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A bstract. Cellular immune responses can destroy cancer cells, achieving the cure of experimental mali gnancies.
An expanding wealth of knowledge on the molecular basis of how to prime and amplify a T cell re sponse has
fueled a number of strategies successful at treating established tumors (rather than merely p	 reventing tumor
g
 rafting). The most efficacious approaches operate at different stages, including: 1) priming the immune response
u sing tumor antigen-expressing dendritic cells or tumor cells transfected with genes that render  them immu-
nogenic, 2) sustaining and amplifying immunity using agonistic monoclonal antibodies against costimulatory
m olecules or immune-potentiating cytokines, and 3) eliminating mechanisms that self-regula te the strength of the
immune response, such as inhibitory receptors or regulatory T cells. A rational combination of such approaches
holds great hope for cumulative and synergistic effects, but there is also evidence that they  can open the
flood-gates for unwanted inflammatory reactions. The next decade can be envisioned as the time when the first
r eproducibly efficacious combination regimes for cancer immunotherapy will become availab le and widely used
in the clinic, as clinicians learn the best strategies and try to harness their potentially damag
 ing effects.
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Antitumor T Cell Priming (Start the Engine)
Tumor cells are antigenic. Many antigenic determi-
n ants are encoded by their genes as a result of muta-
t ions or ectopic expression4

, 5, 41
. Many of them have
b een molecularly defined and the interactions of several
d eterminants with MHC antigen-presenting molecules
h ave been studied. However, tumor cells are very poor-
ly immunogenic in the sense that they do not ignite
a  T cell mediated-immune response by themselves, or
if they do, the response is of rather low intensity4
 1
.
A hot topic these days is whether tumors induce
t olerance towards their antigens or if their antigens are
simply ignored by the immune system46. Experimental
e vidence delivers examples of both modes of action,
a lthough in most instances fully-established tolerance,
a s such, cannot be demonstrated and ignorance is the
most prevalent mechanism9

. In fact, tumor cells per-
f orm very poorly as antigen-presenting cells, even to
induce tolerance by clonal anergy (or deletion) of
T  cells9

. Response or tolerance against tumor antigens
o ccurs as a result of a complex process called cross-
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-presentation in which tumor antigens are taken up,
t ransported and presented by a cell professional for
t hose tasks21. Importantly, cross-presentation, either for
cﬁ ross-priming or for tolerance, needs a certain thre-
shold in the level of antigen expression that, if not
reached, results in immune ignorance to the antigen21.
T herefore, several requirements are to be fulfilled in
o rder to start a T cell response to a tumor antigen:
1) transport of the antigen to lymphoid tissue to meet
n aive T cells, 2) presentation on a cell with the correct
a rray of costimulatory molecules, antigen-presenting
molecules and cytokines, and 3) presence of responsive
e lements in the T cell repertoire5
ﬂ 7
. The first two re-
qﬃ uirements are satisfied if the antigen is given in a form
t hat finally results in its expression on mature dendritic
cﬁ ells (DC)1. The presence of a responsive T cell reper-
t oire depends on the ability of the tumor to tolerize
a gainst its antigens.
T wo general approaches have been followed:
a ) transfection of cytokines and costimulatory mole-
cﬁ ules into tumor cells to make them resemble functional
D C, and b) an artificial loading of tumor antigens on
selected or cultured DC. Either approach has been suc-
cﬁ essful in priming the response against murine tumors.
T hese strategies dominate, in various forms, the current
a rena of tumor vaccination strategies41.
E xpression of DC genes in tumor cells can be
a chieved by in vitro transfection or by in vivo gene
t ransfer of tumor nodules with a number of viral vec-
t ors. The best results with this approach are obtained
b y transfection of granulocyte-macrophage colony-sti-
mulating factor (GM-CSF)12, 22, a molecule that largely
w! orks by easing cross-priming. This is because it
a ttracts and differentiates DC. Interleukin 12 (IL-12)
a lso works well but, again, the cellular events actually
e licited probably rely on cross-presentation mechan-
i sms and the induction of a cascade of cytokines with
p	 leotropic functions on leukocyte biology and an-
g
 iogenesis3
" 8, 53
. Gene transfer of surface molecules of
t he B7 family10, MHC class II2
#
, 47
, 4-1BBL19, 36 and
C$ D40L5
ﬂ
4
 have been found to be efficacious, but most
o ften they are unable to tackle well-established or pro-
l% iferated disease.
A major break-through in the field was the possi-
b ility to culture DC from monocytes of bone-marrow
p	 recursors in the presence of GM-CSF and IL-42
# 3, 50
.
This made feasible the proof-of-concept type of ex-
p	 erimentation, showing that tumor antigens pulsed on
D C were extremely potent tumor vaccines. Sources of
a ntigen can contain single or multiple antigenic deter-
m inants which are given to DC as peptides or a mixture
o f tumor antigens4
 0
. Complex sources of tumor antigens
a re provided as tumor lysate, tumor apoptotic bodies,
cﬁ ell fusion of DC and tumor cells, transfection of total
t umor RNA, etc. Viral and bacterial vectors can be used
t o lead the antigens into the antigen-presenting ma-
cﬁ hinery of DC5
ﬂ 6
. An alternative has been to inject DC
into malignant tissue in such a way that the artificially
i njected DC take up antigens and transport them2# 5, 37, 45.
C$ omplex sources of antigens are better, since they in-
d uce a polyclonal type of response against multiple epi-
t opes at the same time (therefore making antigen-loss
v& ariants less likely) 40. However, they could vaccinate
a gainst normal sequences shared by proteins in the
t umor and normal tissue, leading to autoimmunity.
Many clinical trials are currently testing the best source
o f DC (monocyte-derived, CD34-derived, or Flt-3L-mo-
b ilized)13, 14, 56, the best source of tumor antigen, and
t he most convenient route of injection. The winning
results so far have been for the tumor-cell/DC hybrido-
m as17, 18, which show impressive efficacy in human
renal cell carcinoma27, but such data are under investi-
g
 ation due to a well-founded suspicion of misconduct3
"
.
A'  very appealing source of antigen is tumor pro-
t eins of the heat shock protein family (HSP-70 and
g
 p96) that chaperone peptides in the MHC class
I  antigen-presenting pathway and have been shown to
b e very efficiently internalized in DC49, while they also
p	 rovide cytokine-like activation signals to these cells.
This approach is being currently tested with cancer pa-
t ients.
Costimulation and Immune-Response
M( aintainance (Step on the Gas Pedal)
The immune system has some tricks that can be
e xploited in order to amplify a response. A great num-
b er of cytokines and membrane-bound costimulatory
ligands are able to upregulate and shape the type of
e ffector response. These mechanisms can be grossly
e xaggerated by properly engineered therapeutic agents
in order to get a better antitumor immune response.
In a way, a very simple means to obtain this ampli-
f ication is to repeat the immunization procedure se-
qﬃ uentially over time. If tumor cells present the antigens
i n a poorly immunogenic fashion, repeated doses of the
a ntigens under immunogenic conditions is a good idea,
since these repetitions will not let the immune response
fade away3
" 1
.
I f a patient is successfully primed by active immu-
notherapy, this can allow the physician to culture his
e ffector T cells e) x vivo to be reinfused as adoptive ther-
a py6
*
1
. The artificial culturing of these lymphocytes
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b enefits greatly from this successful priming to increase
T cell precursor frequencies3
" 5
. Therefore, active and
p	 assive or adoptive immunotherapy are to be combined
i n the clinic to sustain the response, as has been shown
in animal models.
Administration of cytokines, either as proteins or
w! ith gene-transfer approaches, can also help the re-
sponse. Type I interferons and IL-2 may find a role in
t hese therapy combinations. Particularly interesting is
t he exploration of the use of IL-15, GM-CSF and Flt-
-3L, which are very promising agents. IL-15 has unex-
p	 ected properties not shared with IL-2, since it expands
m emory cytotoxic T lymphocytes (CTLs) and prevents
a ctivation-induced cell death6
*
, 29, 62
. Flt-3L and GM-
-CSF, to a lesser extent, promote the differentiation and
a ccumulation of great numbers of DC in the treated
subjects3" 2, 33. This has an antitumor immune effect p+ er
s, e3
" 2
 and permits an easier isolation and manipulation of
D C14.
A number of agonistic antibodies against costimu-
l% atory molecules seem to greatly increase the antitumor
i mmune response. This is the case of anti-4-1BB mono-
cﬁ lonal antibodies (mAb)3" 9, which recognize a surface
g
 lycoprotein expressed only on activated T and natural
k- iller cells, providing a very potent costimulatory sig-
nal to activated CTLs throughout the body. These anti-
b odies rely on some level of pre-existing T cell priming
t o activate the expression of 4-1BB on T cells2
# 6
. Agon-
istic antibodies against CD40, which activate antigen-
-presenting cells in all lymphoid tissues, also have great
p	 otential, according to data obtained in mouse tumors16, 58.
Here the anti-CD40 mAb reaches and activates, among
m any others, the small number of DC cross-presenting
t umor antigens and license them to activate CTLs5
ﬂ
1
. Its
function is reminiscent of a physiological concomitant
Th1 response activating DC through CD40L/CD40 in-
t eractions.
O. ther means to accelerate the immune response
w! ill be very likely found by selectively inhibiting
a ctivation-induced cell death of T cells. Such
a  mechanism offers a target to be manipulated and
e xploited in order to strengthen the cellular immune
r esponse. In this regard, a number of B7-like mole-
cﬁ ules are being discovered which may mediate these
f unctions.
Finally, a major hurdle on the pathway of cancer
immunotherapy is the low migration of T cells into ma-
lignant tissue20. Such migration is controlled by chemo-
k- ines and adhesion molecules on endothelial cells,
w! hich are upregulated under inflammatory conditions.
A' ddressing effector T cells to cancer tissue by manipu-
lating the expression of such molecules, making the
t umor look like an inflamed tissue, is a very attractive
p	 ossibility3
"
4, 42
.
Fighting the Immune Self-Regulation
Mechanisms (Release the Brakes)
The immune system has mechanisms that bring the
immune responses to an end and downsize the clonal
e xpansions of lymphocytes. On the other hand, certain
p	 hysiological systems seem to set thresholds and
cﬁ heck-point requirements for cellular immunity to
p	 roceed. Examples of these mechanisms that have been
e xploited in tumor immunotherapy are the cytotoxic
T  lymphocyte antigen 4 (CTLA-4) receptor of T cells
a nd, more recently, immunoregulatory CD4+C$ D25+
T cells.
Anti-CTLA-4 antibodies block negative signals that
d ownregulate T cell expansion8, 60. This molecule, ex-
p	 ressed selectively on activated T cells, recruits tyro-
sine phosphatases that inhibit CD28-mediated T cell
cﬁ ostimulation. In fact, CTLA-4–/– mice develop, in
a  matter of weeks, a severe autoimmune disease with
lymphocyte infiltration in non-lymphoid tissues. Treat-
m ent with CTLA-4 mAb, presumably blocking its
function in vivo, erradicates some malignancies and
synergizes with vaccination with tumor cells expressing
G/ M-CSF7
0
, 8, 59, 60
. In the latter case, autoimmunity in
t he form of vitiligo has been found in mice as well as
in human melanoma patients.
R1 ecently, CD4+2 C$ D25+2  T cells have entered the
limelight of immunology as suppressor cells of the im-
m une response11, 24, 28, 55. They have been found to be
v& ery much involved in maintaining tolerance to self
t issues. The mechanisms that they use to execute these
a ctions are dependent on cell contact and involve T-T
a nd T-DC interactions4
 8
. No information has been pub-
lished on the molecular players of their effector func-
t ion. Anti-CD25 antibodies deplete this subpopulation
a nd are known to increase the antitumor immunity, in
p	 articular in synergy with other means of treatment (i.e.
w! ith vaccination with peptide in adjuvant). This deple-
t ion must be performed before the immunization pro-
cﬁ edure, because the depleting anti-CD25 antibody
w! ould otherwise deplete the T cells that are becoming
a ctivated, since CD25 is expressed on activated lym-
p	 hoblasts.
The molecular targets involved in this control
a gainst overactivation of the immune response will be
a  productive area of research. A race in the search for
a ttractive candidates has started. Infiltration of non-lym-
p	 hatic tissues by activated lymphocytes has also been
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r eported in PD-1–/– mice15, 44, albeit less intense than
t hat observed in CTLA-4–/– mice. Neutralization of the
immune downregulating effects of TGF-β is another
f ield of interest.
… and Get Ready to Face Autoimmunity
Rolf Zinkernagel and coworkers published a paper
i n which mice developed autoimmunity after immuni-
zation against surrogated tumor antigens with DCs. In
t heir model, tumor cell lines and a target transgenic
o rgan shared artificial expression of a viral antigen3
" 0
.
In their experiments, tumor rejection correlated consist-
e ntly with severe autoimmunity. Although this is an
i mportant warning call, data from other experiments
a nd from the battlefield of clinical trials are not so
w! orrisome13, 43, since DC vaccination is known to pres-
e nt self proteins but do not elicit autoimmunity (at least
frequently and seriously enough to be a problem). For
i nstance, in mice transgenic for an antigen of hepatitis
B3  virus expressed in the liver, vaccination with antigen-
-pulsed DC leads to CTL generation, but without liver
a utoimmunity5
ﬂ
2
. However, if these T cells are expanded
in vitro and reinfused, acute hepatitis takes place, indi-
cﬁ ating the existence of some control mechanisms. In
f act, loading DC with complex sources of tumor anti-
g
 ens containing plenty of normal sequences has not
resulted in serious autoimmune conditions.
W4 e do not know what the case will be if we tamper
w! ith the control systems and, at the same time im-
munize intensively. Probably, serious adverse reactions
w! ill be witnessed. The scenario would be reminiscent
o f acute and chronic graft-versus-host reactions in al-
logeneic bone-marrow transplantation. But do not for-
g
 et that if we are to fight cancer with these weapons,
w! e have to take some risks. The spectrum of organ
d amage that can take place is difficult to predict, as is
w! hether the reactions will be acute and self limited or
maintained, reaching chronicity.
Conclusion
O. ur immunotherapeutic arsenal against cancer has
increased incredibly in the last decade. Activity against
mouse tumor models has been unprecedented and the
results in clinical trials are encouraging. We postulate
t hat the ultimately sucessful regimes will consist in
a  combination of interventions based on each of the
t hree different elements described: priming, amplifica-
t ion and removal of the inhibitions. The potency of the
cﬁ ombination will very likely challenge us with some
a utoimmune adverse effects and, hopefully, we will
learn to tilt the balance to the interest of the patient.
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